Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:56:10 EDT Sun 14 Jun 2026
Enter Symbol
or Name
USA
CA



News last 24 hour(s) - 26 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2026-06-14 20:48U:FFAINews ReleaseFaraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: Provides New Details on the FF EAI Robotics Education Ecosystem Strategy, Product Line & New EAI Device Launch Happening at Its Los Angeles HQ on June 16
2026-06-14 20:32U:RSGOFNews ReleaseResouro Strategic Metals Inc. (RSGOF) PEA milestone for Tiros Project
2026-06-14 20:21U:SXOOFNews ReleaseSt-Georges Complete une Premiere Tranche de son Offre de Financement
2026-06-14 20:20U:SXOOFNews ReleaseSt-Georges Closes a First Tranche of a Financing Offering
2026-06-14 19:30U:AAPGNews ReleaseAscentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress
2026-06-14 19:19U:EXCNews ReleaseComEd Reaches 99% Restoration Following Multi-Day Severe Storm Event
2026-06-14 19:03U:CVMNews ReleaseCEL-SCI Corporation Announces Pricing of Offering
2026-06-14 18:05U:ZYMENews ReleaseZymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
2026-06-14 17:00U:PMETFNews ReleaseConcept Study Identifies Potential Refining Pathway at Shaakichiuwaanaan to Battery-Grade Lithium Carbonate
2026-06-14 17:00U:PMETFNews ReleaseConcept Study Identifies Potential Refining Pathway at Shaakichiuwaanaan to Battery-Grade Lithium Carbonate
2026-06-14 17:00U:OSKNews ReleaseOshkosh Defense Highlights Proven, Adaptable Tactical Mobility Solutions for Europe at Eurosatory 2026
2026-06-14 16:35U:MIRMNews ReleaseMirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
2026-06-14 16:35U:INCYNews ReleaseMirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
2026-06-14 16:30U:CRNXNews ReleaseCrinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026
2026-06-14 15:26U:ELEKNews ReleaseElektros Inc. Advances Its Lithium and EV Innovation Strategy as Global Electrification Momentum Accelerates
2026-06-14 14:55U:ELEKNews ReleaseElektros Inc. Strengthens Its Position in Lithium and EV Innovation as the Global Electrification Era Gains Momentum
2026-06-14 14:45U:CRNXNews ReleaseCrinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY(TM) (paltusotine) Provides Durable, Consistent Acromegaly Control
2026-06-14 14:36U:ELEKNews ReleaseElektros Inc. Highlights Long-Term Lithium and EV Innovation Strategy as Global Investors Focus on the Future of Electrification
2026-06-14 14:15U:ELEKNews ReleaseElektros Inc. Embraces the Bright Future of Lithium and EV Innovation as Its Global Electrification Mission Continues to Advance
2026-06-14 11:45U:AVAVNews ReleaseAV Introduces TOM 50 RE, a Backpackable UGV for Rapid Reconnaissance and Explosive Ordnance Disposal
2026-06-14 10:21U:CLDXNews ReleaseCelldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting
2026-06-14 10:00U:UPBNews ReleaseUpstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026
2026-06-14 10:00U:MLYSNews ReleaseMineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)
2026-06-14 05:15U:CLDXNews ReleaseCelldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
2026-06-14 03:15U:LLYNews ReleaseLilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
2026-06-14 03:15U:LEGNNews ReleaseLegend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma